Arctic Vision Joins Forces with the University of Hong Kong Department of Ophthalmology to Discover and Develop Novel Neuroprotective Therapies for Ocular Disease
News provided by
Share this article
Share this article
SHANGHAI and HONG KONG, July 4, 2021 /PRNewswire/ Arctic Vision, a China-based clinical-stage ophthalmology company focuses on developing innovative therapies for pan-ocular diseases, announcing today a new research collaboration with Prof. Christopher Leung, Head and Clinical Professor at the Department of Ophthalmology of the University of Hong Kong (HKU) for the discovery and development of novel neuroprotective therapies for glaucoma.
Glaucoma, an optic neuropathy characterized by progressive loss of retinal ganglion cells (RGCs), is the leading cause of irreversible blindness worldwide.